EasyCookieInfo

31 March 2020 – Takis on the Italian TV program “Otto e mezzo”

Luigi Aurisicchio, CEO/CSO of Takis and Evvivax, in Skype connection on the Italian TV program “Otto e mezzo” conducted by Lilli Gruber.

They talked about the economic impact of Covid-19 and the efforts of researchers all over the world  to find therapeutics and vaccines against the coronavirus. The coordinated work of EMA (European Medicins Agency) and FDA (Food and Drug Administration) may speed up vaccine testing and approval process, which may take about one year.

Takis and the other companies and research institutes that are developing vaccines are working together and sharing data and information in order to learn from each other and reach the goal as soon as possible. This is not a race: even if only one finds a vaccine, we all win.

Hopefully this is a big paradigm shift for scientists, drug developers and regulators. Furthermore, this can be a chance for Italy to start believing and investing a little more in scientific research and development.

Watch the videos:

https://bit.ly/2JulYIL - https://bit.ly/2xMLMwT

 

 

 

25 March 2020 – Takis on the Italian TV program “Presa Diretta”

Have a look at our young and talented researchers while they are working on the development of Covid-19 vaccine in our laboratories based in Castel Romano!

Luigi Aurisicchio, CEO/CSO of Takis and Evvivax, explains in Skype connection on “Presa Diretta” what we are doing in our Labs to create a genetic vaccine against Sars-Cov-2 coronavirus.

We realized a prototype and we are going to test it on animal models. We are also making contact with foreign companies for large sclae production and raising funds for the clinical trial.

Research never stops.

Watch the video

 

 

 

24 Marzo 2020 - Takis e il Dr Ascierto insieme per combattere il COVID-19

Da anni, l’istituto Pascale di Napoli è alla frontiera dell’Immunoterapia del Cancro. I ricercatori ed i medici rappresentano non solo l’eccellenza italiana, ma anche mondiale per l’attuazione di strategie terapeutiche e combinazioni di farmaci a beneficio dei pazienti.

La Takis e il Dr Paolo Ascierto sono collaboratori da anni per lo sviluppo di vaccini contro il melanoma e di terapie innovative, come gli anticorpi monoclonali. Conoscendo bene la nostra Tecnologia, che ha buone probabilità di successo anche contro il COVID-19 è logico pensare alla collaborazione tra le due istituzioni per lo sviluppo ed uno studio clinico, a maggior ragione dopo i successi ottenuti con il Tocilizumab.

Dopo i recenti servizi giornalistici che non rendono onore all’impegno quotidiano dei nostri scienziati e del Pascale, la Takis è e sarà sempre a fianco del Dr Ascierto.  Siamo orgogliosi della sua collaborazione e contiamo di portare il più presto possibile un vaccino contro il COVID-19 alla fase clinica con lui.

//video.sky.it/news/cronaca/virus-ascierto-sperimenteremo-il-vaccino-su-coronavirus/v582530.vid

For donations: https://www.gofundme.com/f/il-vaccino-italiano-contro-covid19

23 March 2020 – Takis on “Il Corriere”: from cancer immunotherapy to Covid-19 vaccine

Takis is an Italian company, founded by a small group of researchers who never thought of leaving Italy, despite the difficulty in doing good scientific research in this country .

This is a story of sacrifices, but also of success. After years of research in the field of anticancer immunotherapy, our experience has led us to take the field against Covid-19. We can and must help fight this pandemics.

We are proud not to have given up and to represent the excellence of Italian research in Europe and worldwide.

Read the article: https://bit.ly/3dNPOFV

 

 

 

 

21 March 2020 – Takis on the national Chinese TV CGTN

Our CEO Luigi Aurisicchio has been interviewed on the national Chinese TV CGTN about Takis commitment to develop a Covid-19 genetic vaccine.

He described how we designed the vaccine starting from the genetic sequence published in January by Chinese researchers and how we are going to proceed in the next months with preclinical and clinical tests.

Read the full interview: https://bit.ly/2WBqtZJ